Table 1.
Demographic and clinical characteristics of BU+HIV+ co-infected patients
| Parameters | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|---|---|---|---|---|---|---|---|---|---|
| Sex | Male | Male | Male | Male | Female | Female | Female | Female | Female |
| Age (years) | 43 | 42 | 45 | 48 | 50 | 38 | 27 | 40 | 18 |
| Lesion form | Ulcer | Ulcer | Ulcer | Ulcer | Ulcer | Ulcer | Ulcer | Nodule | Ulcer |
| Number of lesions | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Category of lesion(s) | II | III | II | I | II | II | I | I | II |
| Lesion site | Upper limb | Lower limb | Lower limb | Lower limb | Back | Lower limb | Lower limb | Lower limb | Upper limb |
| Lesion healing week | 16 | 52 | LF | 12 | 36 | 20 | 12 | 4 | 4 |
| Occurrence of Paradoxical reaction (PR) | No | No | No PR | No PR | No PR | Yes (at week16) | No PR | No PR | No PR |
| Type of PR | NA | NA | NA | NA | NA | EWP | NA | NA | NA |
| HIV load (copies/mL) | |||||||||
| Baseline | 224,856 | 134 | I | 255,950 | 17,538 | 76,448 | ND | ND | ND |
| After BU treatment | 1988 | LF | LF | 1,318,694 | 140 | 25,272 | 60 | 2,576,972 | 13,227 |
| CD4 count | |||||||||
| Baseline | |||||||||
| After BU treatment | 130.02 | 750.3 | 815.04 | 753.532 | 80.6 | ||||
| Haemoglobin (g/dL) | |||||||||
| Baseline | 11.7 | 11 | 10.3 | 10.3 | 9.8 | 9.8 | 11.8 | 8.7 | 9.7 |
| After treatment | 12.5 | LF | LF | 9.3 | 9.8 | 9.1 | 10.7 | 5.61 | ND |
| Weight (Kg) | |||||||||
| Baseline | 63 | 56 | 50 | 42 | 45 | 66 | 44 | 49 | 52 |
| After treatment | 62 | 60 | 55 | 44 | 49 | 67 | 46 | 43 | 60 |
| Hepatitis B virus | – | – | + | – | – | – | – | – | – |
| Hepatitis C virus | – | – | – | – | – | – | – | + | – |
| Buruli ulcer regimen | RS | CR | RS | RS | RS | CR | RS | RS | RS |
| HIV treatment | 3TC, d4T, EFV | not known | not known | not known | 3TC, TDF, NVP | 3TC, TDF, NVP | AZT, 3TC, NVP | AZT, 3TC, EFV | Not known |
| Patient on ART before initiation of BU treatment | No | NA | NA | NA | No | Yes | No | Yes | NA |
Abbreviations: − Negative, + Positive, RS Rifampicin and Streptomycin, CR Rifampicin and Clarithromycin, LF Lost to follow-up, I Invalid result, ND Not done, d4T Stavudine, 3TC Lamivudine, NVP Nevirapine, TDF Tenofovir, AZT Zidovudine, EFV Efavirenz, PR Paradoxical reaction, NA Not applicable, EWP Enlarged, warm to touch lesion